Fig. 2: A subset of NJs are expressed tumour-wide.
From: Tumour-wide RNA splicing aberrations generate actionable public neoantigens
a, Overview of tumour-wide NJ characterization using RNA-seq data from multiple intratumoural regions in various cancer types. S1–S6 indicate an example numbering of samples isolated per patient. b, Heat maps representing log2[CPM] for NJs (rows) across five intratumoural regions in COAD, KICH, LIHC and STAD, with tumour-wide NJs highlighted in yellow. c, Heat map illustrating the proportion of intratumoural regions with detectable NJ expression (rows) in LIHC (left), PRAD (centre) and MESO (right). Each column represents a single patient. d, Three-dimensional brain and tumour (yellow) models for patient 470. Approximately 10 spatially mapped and maximally distanced biopsies (blue) were taken in each tumour (refer to Supplementary Video 1). e, Heat map of NJ (rows) expression across glioma subtypes: IDHwt (blue), IDHmut-A (yellow) and IDHmut-O (red). Columns represent patients, and cell intensity indicates the percentage of intratumoural regions expressing each NJ. f,g, NJ ITH in gliomas (n = 789) shown using a bar plot (f) and parts-of-whole chart (g). NJs are classified as: tumour-wide (100% intratumoural regions, red), highly conserved (>70%, orange), moderately conserved (>30% to ≤70%, yellow), or weakly conserved (≥1 region but ≤30%, green). In f, the data are represented as box plots, in which the median line represents the 50th percentile. Further statistical details are provided in Supplementary Table 3. a, Created in BioRender (credit: D.W.K., https://BioRender.com/h58s281; 2024).
